Figure 2.
ETS1 expression is upregulated in NA-ATLL cell line and primary tumor cells. (A) RNA-seq ETS1 expression in NA-ATLL (n = 4) compared with J-ATLL (n = 4) cell lines. Mean ± standard error (SE); 2-sided t test; TPM, transcripts per million. (B) Western blot validation of ETS1 expression across ATLL cell lines. ETS1 relative abundance is normalized to total protein. (C) ETS1 expression is elevated in NA-ATLL primary tumor cells compared with PBMCs and CD4 T cells derived from healthy donors. RNA-seq; mean normalized read counts ± SE; FDR-corrected P value. (D) ETS1 expression in J-ATLL primary tumor cells compared with healthy donor CD4 cells. FDR-corrected P value. (E) ETS1 expression across ATLL subtypes (P = .113). Chron, Chronic; Smol, Smoldering. (F) ETS1 expression stratified by low and high proviral load (median cutoff: proviral load 78.4%, P = .0018).

ETS1 expression is upregulated in NA-ATLL cell line and primary tumor cells. (A) RNA-seq ETS1 expression in NA-ATLL (n = 4) compared with J-ATLL (n = 4) cell lines. Mean ± standard error (SE); 2-sided t test; TPM, transcripts per million. (B) Western blot validation of ETS1 expression across ATLL cell lines. ETS1 relative abundance is normalized to total protein. (C) ETS1 expression is elevated in NA-ATLL primary tumor cells compared with PBMCs and CD4 T cells derived from healthy donors. RNA-seq; mean normalized read counts ± SE; FDR-corrected P value. (D) ETS1 expression in J-ATLL primary tumor cells compared with healthy donor CD4 cells. FDR-corrected P value. (E) ETS1 expression across ATLL subtypes (P = .113). Chron, Chronic; Smol, Smoldering. (F) ETS1 expression stratified by low and high proviral load (median cutoff: proviral load 78.4%, P = .0018).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal